Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPRT1 | P00492 | 5/20 | 0.55 |
| ▸ | PNP | P00491 | 5/20 | 0.51 |
| ▸ | TK1 | P04183 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | XDH | P47989 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | VCP | P55072 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18479143 | 1.00 | HPRT1 (0.55) | HPRT1PNPTK1MEN1KMT2A | |
| SCHEMBL18476745 | 1.00 | HPRT1 (0.55) | HPRT1PNPTK1MEN1KMT2A | |
| SCHEMBL18474881 | 1.00 | HPRT1 (0.55) | HPRT1PNPTK1MEN1KMT2A | |
| SCHEMBL22759884 | 1.00 | HPRT1 (0.55) | HPRT1PNPTK1MEN1KMT2A | |
| SCHEMBL24317687 | 0.98 | HPRT1 (0.53) | HPRT1PNPTK1MEN1KMT2A | |
| SCHEMBL21943253 | 0.95 | HPRT1 (0.53) | HPRT1PNPTK1MEN1KMT2A | |
| SCHEMBL21385679 | 0.93 | HPRT1 (0.55) | HPRT1PNPTK1MEN1KMT2A | |
| SCHEMBL24529735 | 0.89 | PNP (0.50) | HPRT1PNPTK1MEN1KMT2A | |
| SCHEMBL21516006 | 0.89 | PNP (0.50) | HPRT1PNPTK1MEN1KMT2A | |
| SCHEMBL19661681 | 0.86 | HPRT1 (0.40) | HPRT1PNPALDH1A1LMNACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10758629-B2 | Exon skipping oligomer conjugates for muscular dystrophy | SAREPTA THERAPEUTICS, INC. (US) | 2020-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10758629-B2 | Exon skipping oligomer conjugates for muscular dystrophy | UTRN, SMN1; SMN2, RBM17 | HPRT1 3710/4885PNP 3783/4885TK1 1967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.